2020
DOI: 10.1039/d0bm00787k
|View full text |Cite
|
Sign up to set email alerts
|

Exploitation of human mesenchymal stromal cell derived matrix towards the structural and functional restoration of the ocular surface

Abstract: Decellularized matrix of ADMSCs is a promising conjunctival substitute with superb wound repairing property by promoting proliferation of conjunctival epithelial cells and restoring goblet cells without causing cosmetic differences.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(10 citation statements)
references
References 45 publications
0
10
0
Order By: Relevance
“…[3] Cell-derived dECM is exceptionally suitable for both in vitro research and therapeutic applications. Its value for skeletal tissue engineering, [21][22][23] cardiovascular tissue engineering, [24,25] wound healing, [26,27] and ocular surface reconstruction [28,29] has been extensively explored.…”
Section: Cell-derived Decmmentioning
confidence: 99%
“…[3] Cell-derived dECM is exceptionally suitable for both in vitro research and therapeutic applications. Its value for skeletal tissue engineering, [21][22][23] cardiovascular tissue engineering, [24,25] wound healing, [26,27] and ocular surface reconstruction [28,29] has been extensively explored.…”
Section: Cell-derived Decmmentioning
confidence: 99%
“…Studies revealed that mesenchymal stromal (or stem) cells (MSCs) could survive and differentiate into adult human keratocytes in animal models without eliciting an inflammatory response. In addition, they produced new collagen in the host stroma and were able to remodel scars and improve transparency in animal models for corneal dystrophies [14,15]. Cell-based therapies can be broadly divided into using stem cells to stimulate regeneration with and without scaffolds.…”
Section: Cell-based Therapiesmentioning
confidence: 99%
“…As of February 2022, there were three clinical trials on the ClinicalTrials.gov website ( Table 2 ). In previous studies, MSC treatment of ocular surface diseases mainly included tissue transplantation 65 , periorbital injection 57 , 63 , topical drops 66 , and intravenous injection 67 ( Fig. 2 ).…”
Section: Application Of Mscs In Dry Eye Treatmentmentioning
confidence: 99%